resiquimod has been researched along with Hepatitis C in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Horscroft, N; Laxton, C; Myangar, N; Parkinson, T; Rodman, J; Thomas, A | 1 |
| Anthony, DD; Asaad, R; Heeger, PS; Lederman, MM; Milkovich, KA; Rodriguez, B; Yonkers, NL | 1 |
2 other study(ies) available for resiquimod and Hepatitis C
| Article | Year |
|---|---|
Investigating Toll-like receptor agonists for potential to treat hepatitis C virus infection.
Topics: Antiviral Agents; Cell Line, Tumor; Cytokines; Hepacivirus; Hepatitis C; Humans; Leukocytes, Mononuclear; Toll-Like Receptor 3; Toll-Like Receptor 7; Toll-Like Receptor 9; Toll-Like Receptors | 2007 |
TLR ligand-dependent activation of naive CD4 T cells by plasmacytoid dendritic cells is impaired in hepatitis C virus infection.
Topics: Adult; Antigens, CD; B7-2 Antigen; CD4-Positive T-Lymphocytes; CD83 Antigen; CpG Islands; Dendritic Cells; Hepacivirus; Hepatitis C; HLA-DR Antigens; Humans; Imidazoles; Immunoglobulins; Interferon-alpha; Interleukin-3; Ligands; Lymphocyte Activation; Membrane Glycoproteins; Poly I-C; Toll-Like Receptors; Tumor Necrosis Factor-alpha | 2007 |